Where do Design Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Design Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Returns
Return on equity	-31.3%-0.6pp	-30.7%-0.9pp	-29.8%-3.1pp	-26.8%-4.2pp	-22.6%-3.5pp
Return on assets	-29.8%-0.6pp	-29.2%-0.7pp	-28.5%-2.7pp	-25.8%-4.0pp	-21.8%-3.5pp
Return on invested capital	-37.1%+0.8pp	-37.9%0.0pp	-38%-1.7pp	-36.2%-6.5pp	-29.8%-3.9pp
Efficiency
Asset turnover	0×—	0×—	0×—	——	——
Liquidity
Current ratio	22.3×+5.1×	17.1×-1.6×	18.7×-6.4×	25.1×-3.2×	28.4×-0.9×
Quick ratio	22.3×+5.1×	17.1×-1.6×	18.7×-6.4×	25.1×-3.2×	28.4×-0.9×
Cash ratio	1.3×0.0×	1.3×-0.1×	1.4×-0.9×	2.3×+0.6×	1.7×-1.0×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$3.55-4.2%	$3.71+5.7%	$3.51-6.4%	$3.75-6.7%	$4.02-6.1%
Valuation
Market capitalization	$839.42M+295%	$534.32M+24.6%	$428.82M+90.3%	$225.37M+2.9%	$219.1M-37.3%
Enterprise value	$829.39M+313%	$519M+24.9%	$415.47M+100%	$207.61M0.0%	$207.58M-36.9%
Price / book	3.8×+2.9×	2.5×+0.4×	2.1×+1.1×	1.1×+0.1×	1×-0.5×
Free cash flow yield	-6.4%+16.0pp	-10.2%+2.0pp	-12.2%+10.3pp	-22.5%-0.8pp	-21.8%-9.3pp
Earnings yield	-8.3%+18.2pp	-13.1%+2.7pp	-15.7%+12.4pp	-28.2%-2.5pp	-25.6%-11.5pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Design Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Design Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.